Pharmacodynamics and pharmacokinetics
Pharmacodynamics
The drug is for local use and has anti-allergic and anti-inflammatory effects. Enhances the production of phospholipase A2 ( lipocortin ), inhibits the process of release of arachidonic acid and the synthesis of its metabolic products. Reduces the exudation of the inflammatory process, reduces the intensity of granulation and infiltration, inhibits the migration of macrophages and the formation of chemotaxis, prevents the release of inflammatory mediators from cells, which plays an important role in the mechanism of symptoms of allergic chronic rhinitis .
The drug does not have MCS activity, is well tolerated by patients with long-term use, and does not have a resorptive effect.
Pharmacokinetics
Budesonide is quickly adsorbed after inhalation; the systemic bioavailability of the drug after inhalation through a nebulizer is about 15% of the administered dose. In the blood, the maximum concentration is reached on average after 30 minutes. Binding to blood proteins is high.
Biotransformation of budesonide occurs with the participation of the liver isoenzyme CYP3A4 . The main metabolites have extremely weak pharmacological activity. The drug is excreted by the kidneys, mainly in the form of metabolites (up to 70%) and in small quantities (about 10%) through the intestines.
Side effects
They manifest themselves mainly in the form of local reactions on the nasal mucosa (dryness, burning, irritation). Runny nose , atrophy or ulceration of the nasal mucosa, nosebleeds, sore throat, sneezing, sore throat, headache , allergic reactions on the skin, perforation of the nasal septum, myalgia , conjunctival hyperemia , nasal congestion, drowsiness , cough, nausea, vomiting, palpitations , candidiasis of the nasal and pharyngeal mucosa, growth retardation.
Budenit Steri-Neb, instructions for use (Method and dosage)
The drug is administered by inhalation through an inhaler-nebulizer . Before using it, you must carefully study the instructions and techniques for working with it.
The recommended daily dosage of the drug for severe bronchial asthma for inhaled GCS therapy, for adults and children over 12 years of age is 1–2 mg twice a day, a maintenance dose is 0.5–4 mg per day. At the age of 6 months to 12 years, the daily dosage ranges from 0.25 to 0.5 mg twice a day, the maintenance dose is 0.25–2 mg per day. If the prescribed dose is no more than 1 mg/day, then it can be taken in one dose.
As a rule, the maintenance dose is selected by the doctor individually, and when a therapeutic effect is achieved, it should be reduced to the lowest effective dose. If it is necessary to enhance the therapeutic effect, the dose of the drug can be increased or a combination of the drug with oral corticosteroids is recommended.
Budenit Steri-Neb suspension for ing. 0.25mg/ml 2ml amp.pl. 20 pcs
The drug Budenit Steri-Neb is not intended for rapid relief of attacks of bronchial asthma; to relieve acute bronchospasm, it is recommended to use short-acting inhaled bronchodilators. Patients not receiving GCS Typically, the therapeutic effect occurs within 10 days. In patients with excessive mucus secretion in the bronchi, a short (about 2 weeks) additional treatment with oral corticosteroids may initially be given. After a course of oral therapy, in many cases it is possible to completely stop taking GCS orally.
Patients on GCS therapy Before transferring a patient from treatment with oral GCS to treatment with Budenit Steri-Nab, the patient's condition should be relatively stable.
After which the drug Budenit SteriNeb is used in combination with the previously used dose of GCS for oral administration for about 10 days. Subsequently, the dose of oral corticosteroids should be gradually reduced (for example, by 2.5 mg of prednisolone or its equivalent every month) as far as possible to the lowest level. In most cases, oral GCS can be completely replaced with Budenit Steri-Neb.
Sometimes, during a transfer from treatment with oral corticosteroids to treatment with Budenit Steri-Neb, symptoms that were previously relieved by systemic drugs are observed: for example, rhinitis, eczema and muscle and joint pain. The occurrence of symptoms such as fatigue, headache, nausea and vomiting may indicate the development of systemic insufficiency of GCS. In such cases, it may even be necessary to temporarily increase the dose of oral corticosteroids.
Systemic side effects of inhaled corticosteroids can occur primarily when high doses are administered over a long period of time. The likelihood of this effect occurring is significantly less than with treatment with oral corticosteroids. Possible systemic effects include adrenal suppression, growth retardation in children and adolescents, decreased bone mineral density, cataracts, and glaucoma.
Therefore, it is very important to titrate the dose of inhaled corticosteroids to the lowest dose that maintains effective disease control. It is recommended to regularly monitor growth in children receiving inhaled corticosteroids for an extended period of time. In case of growth retardation, treatment should be adjusted to reduce the dose of GCS for inhalation to the lowest dose at which effective control of bronchial asthma is maintained.
Oral administration of ketoconazole and itraconazole or other inhibitors of the CYP3A4 isoenzyme increases the systemic exposure of budesonide.
Therefore, if combined use is necessary, they should be taken at maximum intervals.
A dose reduction of budesonide should also be considered.
To minimize the risk of fungal stomatitis, the patient and/or the child’s parents should be informed about the need to rinse the mouth with water after each inhalation of the drug.
Effect on the ability to drive a vehicle and operate equipment The drug Budenit Steri-Neb does not have a negative effect on the ability to drive a vehicle and operate equipment. In case of rare adverse reactions from the nervous system, activities that require rapid psychomotor reactions should be avoided.
Technique of use Ultrasonic nebulizers are not suitable for use with the drug Budenit Steri-Neb. The dose required by the patient may vary depending on the nebulizer used. Inhalation time and dose of the drug depend on the air flow speed, the volume of the nebulizer chamber and the filling volume.
Therefore, to inhale the drug Budenit Steri-Neb, it is necessary to use an appropriate nebulizer, as well as a mouthpiece and a special face mask.
The nebulizer must be connected to an air compressor to create adequate air flow.
Before using the drug, you must read the instructions from the nebulizer manufacturer.
— Prepare the nebulizer according to its manufacturer’s instructions.
— Separate the STERI-NEB (ampoule with a sterile solution) from the block by turning and pulling it.
— Holding the ampoule vertically with the cap up, break off the cap.
— Squeeze the solution into the nebulizer reservoir.
— Use the nebulizer according to its manufacturer's instructions.
- You should rinse your mouth after finishing inhalation. If you used a mask, you must rinse your face.
— The solution remaining unused in the nebulizer chamber should be discarded.
— Wash the nebulizer thoroughly.
When using the drug, you should avoid getting the solution into your eyes.
Analogs of Budenit Steri-Neb
Level 4 ATX code matches:
Alvesco
Asmanex
Beclazon
Budesonide
Flixotide
Pulmicort
Aldecin
Apulein , Budecort , Gorakort , Benacort , Budesonide , Benarin Budenofalk , Buderin , Cicortide Cyclocaps , Budiair , Pulmicort , Tafen Nasal .
Reviews of Budenit Steri-Neb
Reviews of the drug from most patients are positive:
- “... The doctor diagnosed my child with chronic obstructive bronchitis, bronchial asthma is in question. We periodically undergo treatment in the allergy department”;
- “... After discharge, the doctor prescribed Budenit Steri-Neb inhalations for severe wheezing and coughing attacks. The drug stops attacks well, but we are afraid to take it often, because it contains hormones.”
Many patients on forums on the Internet are interested in: “Budenit Steri-Neb or Pulmicort - which is better?” If we talk about an inhalation suspension as a form of release of the drug for a nebulizer, then there are no significant differences. Same active ingredient, similar indications for use. However, there is a slight difference in the cost of these drugs in the pharmacy chain.
Budenit Steri-Neb, 0.25 mg/ml, dosed suspension for inhalation, 2 ml, 20 pcs.
The drug Budenit Steri-Neb is not intended for rapid relief of attacks of bronchial asthma. To relieve acute bronchospasm, it is recommended to use short-acting inhaled bronchodilators.
Patients not receiving GCS
Usually the therapeutic effect occurs within 10 days. In patients with excessive mucus secretion in the bronchi, short (about 2 weeks) additional treatment with oral corticosteroids may initially be given. After a course of oral therapy, in many cases it is possible to completely stop taking GCS orally.
Patients on GCS therapy
Before transferring a patient from treatment with oral corticosteroids to treatment with Budenit Steri-Nab, the patient's condition should be relatively stable. After which the drug Budenit Steri-Neb is used in combination with the previously used dose of GCS for oral administration for about 10 days. Subsequently, the dose of oral corticosteroids should be gradually reduced (for example, by 2.5 mg of prednisolone or its equivalent every month) as far as possible to the lowest level. In most cases, oral GCS can be completely replaced with Budenit Steri-Neb.
Sometimes, during the transfer from treatment with oral corticosteroids to treatment with Budenit Steri-Neb, symptoms that were previously relieved by systemic drugs are observed: for example, rhinitis, eczema and muscle and joint pain. The occurrence of symptoms such as fatigue, headache, nausea and vomiting may indicate the development of systemic insufficiency of GCS. In such cases, it may even be necessary to temporarily increase the dose of oral corticosteroids.
Systemic side effects of inhaled corticosteroids may occur primarily when high doses are administered over a long period of time. The likelihood of this effect occurring is significantly less than with treatment with oral corticosteroids. Possible systemic effects include adrenal suppression, growth retardation in children and adolescents, decreased bone mineral density, cataracts, and glaucoma. Therefore, it is very important to titrate the dose of inhaled corticosteroids to the lowest dose at which effective disease control is maintained. It is recommended to regularly monitor growth in children receiving inhaled corticosteroids for an extended period of time. In case of growth retardation, treatment should be adjusted to reduce the dose of GCS for inhalation to the lowest dose at which effective control of bronchial asthma is maintained.
Oral administration of ketoconazole and itraconazole or other inhibitors of the CYP3A4 isoenzyme increases the systemic exposure of budesonide. Therefore, if combined use is necessary, they should be taken at maximum intervals. A dose reduction of budesonide should also be considered.
To minimize the risk of fungal stomatitis, the patient and/or the child’s parents should be informed about the need to rinse the mouth with water after each inhalation of the drug.
Impact on the ability to drive a vehicle and operate machinery.
The drug Budenit Steri-Neb does not have a negative effect on the ability to drive a vehicle or operate machinery. In case of rare adverse reactions from the nervous system, activities that require rapid psychomotor reactions should be avoided.
Technique of use
Ultrasonic nebulizers are not suitable for use with Budenit Steri-Neb. The dose required by the patient may vary depending on the nebulizer used. Inhalation time and dose of the drug depend on the air flow speed, the volume of the nebulizer chamber and the filling volume. Therefore, to inhale the drug Budenit Steri-Neb, it is necessary to use an appropriate nebulizer, as well as a mouthpiece and a special face mask. The nebulizer must be connected to an air compressor to create adequate air flow.
Before using the drug, you must read the instructions from the nebulizer manufacturer.
1. Prepare the nebulizer according to its manufacturer's instructions.
2. Separate STERI-NEB (ampoule with a sterile solution) from the block by turning and pulling it (Fig. 1).
Picture 1.
3. Holding the ampoule vertically with the cap up, break off the cap (Fig. 2).
Figure 2.
4. Squeeze the solution into the nebulizer reservoir (Fig. 3).
Figure 3.
5. Use the nebulizer according to its manufacturer's instructions.
6. Rinse your mouth after finishing inhalation.
7. If a mask was used, it is necessary to rinse your facial skin.
8. The solution remaining unused in the nebulizer chamber should be discarded.
9. Wash the nebulizer thoroughly.
10. When using the drug, avoid getting the solution into the eyes.
Price Budenit Steri-Neb, where to buy
The price of Budenit Steri-Neb suspension ampoules 0.25 mg/ml, 2 ml, No. 20 varies from 725 to 1120 rubles per package. Ampoules 0.5 mg/ml 2 ml No. 20 988 - 1280 rubles. You can buy Budenit Steri-Neb in the pharmacy chain of Moscow and other Russian cities without any difficulty.
- Online pharmacies in RussiaRussia
ZdravCity
- Budenit Steri-Neb susp.
d/ing. dosed 0.25 mg/ml amp. 2ml 20pcs Ivex Pharmaceuticals Ukey Limited RUR 471 order - Budenit Steri-Neb susp. d/ing. dosed 0.25 mg/ml 2 ml 60 pcs Norton Healthcare Limited
RUB 1,577 order
Budenit steri-neb
The drug Budenit Steri-Neb is not intended for rapid relief of attacks of bronchial asthma; to relieve acute bronchospasm, it is recommended to use short-acting inhaled bronchodilators.
Patients not receiving GCS
Usually the therapeutic effect occurs within 10 days. In patients with excessive mucus secretion in the bronchi, a short (about 2 weeks) additional treatment with oral corticosteroids may initially be given. After a course of oral therapy, in many cases it is possible to completely stop taking GCS orally.
Patients on GCS therapy
Before transferring a patient from treatment with oral corticosteroids to treatment with Budenit Steri-Nab, the patient's condition should be relatively stable. After which the drug Budenit Steri-Neb is used in combination with the previously used dose of GCS for oral administration for about 10 days. Subsequently, the dose of oral corticosteroids should be gradually reduced (for example, by 2.5 mg of prednisolone or its equivalent every month) as far as possible to the lowest level. In most cases, oral GCS can be completely replaced with Budenit Steri-Neb.
Sometimes, during a transfer from treatment with oral corticosteroids to treatment with Budenit Steri-Neb, symptoms that were previously relieved by systemic drugs are observed: for example, rhinitis, eczema, muscle and joint pain. The occurrence of symptoms such as fatigue, headache, nausea and vomiting may indicate the development of systemic insufficiency of GCS. In such cases, it may even be necessary to temporarily increase the dose of oral corticosteroids.
Systemic side effects of inhaled corticosteroids can occur primarily when high doses are administered over a long period of time. The likelihood of this effect occurring is significantly less than with treatment with oral corticosteroids. Possible systemic effects include adrenal suppression, growth retardation in children and adolescents, decreased bone mineral density, cataracts, and glaucoma. Therefore, it is very important to titrate the dose of inhaled corticosteroids to the lowest dose that maintains effective disease control. It is recommended to regularly monitor growth in children receiving inhaled corticosteroids for an extended period of time. In case of growth retardation, treatment should be adjusted to reduce the dose of GCS for inhalation to the lowest dose at which effective control of bronchial asthma is maintained.
Oral administration of ketoconazole and itraconazole
or other inhibitors of the CYP3A4 isoenzyme
increases the systemic exposure of budesonide. Therefore, if combined use is necessary, they should be taken at maximum intervals. A dose reduction of budesonide should also be considered.
To minimize the risk of fungal stomatitis, the patient and/or the child’s parents should be informed about the need to rinse the mouth with water after each inhalation of the drug.
Impact on the ability to drive vehicles and operate machinery
The drug Budenit Steri-Neb does not have a negative effect on the ability to drive a vehicle or operate machinery. In case of rare adverse reactions from the nervous system, activities that require rapid psychomotor reactions should be avoided.
